CAIX-targeted PET/CT in Solid Tumors
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorZhongnan Hospital
About this trial
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology;
Age of 18 years and above, both male and female are eligible;
The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points;
Research participants voluntarily sign informed consent forms or have their parents/children/legal guardians sign informed consent forms, and are able to complete the trial according to the requirements of the research protocol.
Disqualifiers
Participants with severe liver and kidney dysfunction and cardiac dysfunction;
Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans;
Pregnant or lactating women;
Other situations that researchers believe should be excluded and documented.
Trial design
Design model
Single group
Treatments tested in this trial
68Ga-CAIX
Diagnostic testThe subjects receive a PET/CT scan 30-60 minutes after intravenous administration of 68Ga-CAIX
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: 68Ga-CAIX PET/CT imaging in solid tumorsExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Evaluation of diagnostic performance
To evaluate the diagnostic efficacy of ⁶⁸Ga-CAIX PET/CT imaging in detecting primary and metastatic lesions of malignant solid tumors.
Time frame
up to 6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: